e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 9, 2005
QUESTCOR PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
California
(State or Other Jurisdiction
of Incorporation)
|
|
001-14758
(Commission File Number)
|
|
33-0476164
(I.R.S. Employer
Identification No.) |
|
|
|
|
|
3260 Whipple Road Union City, California
(Address of Principal Executive Offices)
|
|
|
|
94587
(Zip Code) |
Registrants telephone number, including area code:
(510) 400-0700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 1.01. Entry into a Material Definitive Agreement.
On
September 9, 2005, Questcor Pharmaceuticals, Inc. and Computershare Trust Company, Inc.
entered into a First Amendment to that certain Rights Agreement dated February 11, 2003, amending
the definition of Acquiring Person.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
|
|
|
|
|
|
|
10.47
|
|
First Amendment, dated as of
September 9, 2005, to Rights Agreement
dated as of February 11, 2003, between Questcor Pharmaceuticals, Inc. and
Computershare Trust Company, Inc. |
SIGNATURES
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
QUESTCOR PHARMACEUTICALS, INC.
|
|
Date: September 13, 2005 |
By: |
/s/ JAMES L. FARES
|
|
|
|
James L. Fares |
|
|
|
President and Chief Executive Officer |
|
|
EXHIBIT INDEX
|
|
|
Exhibit |
|
|
No. |
|
Description |
10.47
|
|
First Amendment, dated as of
September 9, 2005, to Rights Agreement dated as of February
11, 2003, between Questcor Pharmaceuticals, Inc. and Computershare Trust Company, Inc. |
exv10w47
EXHIBIT 10.47
FIRST AMENDMENT TO RIGHTS AGREEMENT
FIRST
AMENDMENT, dated as of September 9, 2005 (First Amendment), to Rights Agreement dated
as of February 11, 2003 (the Rights Agreement), between Questcor Pharmaceuticals, Inc., a
California corporation (the Company), and Computershare Trust Company, Inc. (the Rights Agent).
Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them
in the Rights Agreement.
WHEREAS, the Company and the Rights Agent previously entered into the Rights Agreement; and
WHEREAS, pursuant to Section 26 of the Rights Agreement, the Company and the Rights Agent may
from time to time supplement or amend any provision of the Rights Agreement in accordance with the
terms of such Section 26.
NOW, THEREFORE, in consideration of the foregoing promises and mutual agreements set forth in
this Amendment, the parties hereby amend the Rights Agreement as follows:
1. Section 1.1 of the Rights Agreement is hereby amended and restated in its entirety as
follows:
Acquiring Person shall mean any Person (as such term is hereinafter defined) who or
which, together with all Affiliates and Associates (as such terms are hereinafter defined)
of such Person, shall be the Beneficial Owner (as such term is hereinafter defined) of 15%
or more of the Common Shares of the Company then outstanding but shall not include (i) an
Exempt Person or (ii) any Existing Holder, unless and until such time as such Existing
Holder shall become the Beneficial Owner of one or more additional Common Shares of the
Company (other than pursuant to (i) a dividend or distribution paid or made by the Company
on the outstanding Common Shares in Common Shares or pursuant to a split or subdivision of
the outstanding Common Shares, (ii) the purchase of up to an additional 800,000 Common
Shares on or after August 8, 2005 by such Existing Holder, or (iii) in the event that the
Company issues additional Common Shares after August 8, 2005 (other than issuances pursuant
to stock option programs or other equity incentive arrangements and issuances pursuant to
the exercise or conversion of securities outstanding on August 8, 2005), the purchase of
additional Common Shares by such Existing Holder so long as such Existing Holder does not
become the Beneficial Owner of a greater percentage of the Common Shares than the percentage
such Existing Holder beneficially owned on August 8, 2005), unless, upon becoming the
Beneficial Owner of such additional Common Shares, such Existing Holder is not then the
Beneficial Owner of 15% or more of the Common Shares then outstanding. Existing Holder
shall mean Sigma-Tau Finanziaria SpA, together with all of its Affiliates and Associates,
including, without limitation Defiante Farmaceutica LDA (formerly known as Defiante
Farmaceutica Unipessoal LDA), Sigma-Tau International S.A. (formerly known as
Sigma-Tau Finance Holding S.A.), Chaumiere Consultadoria & Servicos SDC Unipessoal LDA,
Aptafin SpA, Paolo Cavazza and Claudio Cavazza. Notwithstanding the foregoing, no Person
shall become an Acquiring Person as the result of an acquisition of Common Shares by the
Company which, by reducing the number of shares outstanding, increases the proportionate
number of shares beneficially owned by such Person to 15% or more of the Common Shares of
the Company then outstanding; provided, however, that if a Person shall become the
Beneficial Owner of 15% or more of the Common Shares of the Company then outstanding solely
by reason of share purchases by the Company and shall, after such share purchases by the
Company, become the Beneficial Owner of one or more additional Common Shares of the Company
(other than pursuant to a dividend or distribution paid or made by the Company on the
outstanding Common Shares in Common Shares or pursuant to a split or subdivision of the
outstanding Common Shares), then such Person shall be deemed to be an Acquiring Person
unless upon becoming the Beneficial Owner of such additional shares of Common Stock such
Person does not beneficially own 15% or more of the shares of Common Stock then outstanding.
Notwithstanding the foregoing, if the Board of Directors of the Company determines in good
faith that a Person who would otherwise be an Acquiring Person, as defined pursuant to the
foregoing provisions of this Section 1.1, has become such inadvertently (including, without
limitation, because (A) such Person was unaware that it beneficially owned a percentage of
Common Stock that would otherwise cause such Person to be an Acquiring Person or (B) such
Person was aware of the extent of its Beneficial Ownership of Common Stock but had no actual
knowledge of the consequences of such Beneficial Ownership under this Agreement), and
without any intention of changing or influencing control of the Company, and such Person
divests as promptly as practicable a sufficient number of Common Shares so that such Person
would no longer be an Acquiring Person, as defined pursuant to the foregoing provisions of
this Section 1.1, then such Person shall not be deemed to be or have become an Acquiring
Person at any time for any purposes of this Agreement. For all purposes of this Agreement,
any calculation of the number of Common Shares outstanding at any particular time, including
for purposes of determining the particular percentage of such outstanding Common Shares of
which any Person is the Beneficial Owner, shall be made in accordance with the last sentence
of Rule 13d-3(d)(1)(i) of the General Rules and Regulations under the Securities Exchange
Act of 1934, as amended (the Exchange Act), as in effect on the date of this Agreement.
2. The second paragraph of Exhibit C to the Rights Plan (SUMMARY OF RIGHTS TO PURCHASE
PREFERRED SHARES), is hereby amended and restated in its entirety as follows:
Until the earlier to occur of (i) ten (10) days following a public announcement that a
person or group of affiliated or associated persons has acquired or obtained the right to
acquire, beneficial ownership of 15% or more of the Common Shares (an Acquiring Person)
(other than an Existing Holder (defined as Sigma-Tau Finanziaria SpA, together with all of
its Affiliates and Associates, including, without limitation Defiante Farmaceutica LDA
(formerly known as Defiante Farmaceutica Unipessoal LDA), Sigma-Tau International S.A.
(formerly known as Sigma-Tau Finance Holding S.A.), Chaumiere
2
- Consultadoria & Servicos SDC Unipessoal LDA, Aptafin SpA, Paolo Cavazza and Claudio
Cavazza), unless and until such time as such Existing Holder shall become the Beneficial
Owner of one or more additional Common Shares of the Company (other than pursuant to (i) a
dividend or distribution paid or made by the Company on the outstanding Common Shares in
Common Shares or pursuant to a split or subdivision of the outstanding Common Shares, (ii)
the purchase of up to an additional 800,000 Common Shares on or after August 8, 2005 by such
Existing Holder, or (iii) in the event that the Company issues additional Common Shares
after August 8, 2005 (other than issuances pursuant to stock option programs or other equity
incentive arrangements and issuances pursuant to the exercise or conversion of securities
outstanding on August 8, 2005), the purchase of additional Common Shares by such Existing
Holder so long as such Existing Holder does not become the Beneficial Owner of a greater
percentage of the Common Shares than the percentage such Existing Holder beneficially owned
on August 8, 2005), unless, upon becoming the Beneficial Owner of such additional Common
Shares, such Existing Holder is not then the Beneficial Owner of 15% or more of the Common
Shares then outstanding) or (ii) ten (10) business days (or such later date as may be
determined by action of the Board of Directors prior to such time as any person or group of
affiliated persons becomes an Acquiring Person) following the commencement or announcement
of an intention to make a tender offer or exchange offer the consummation of which would
result in the beneficial ownership by a person or group of 15% or more of the Common Shares
(the earlier of (i) and (ii) being called the Distribution Date), the Rights will be
evidenced, with respect to any of the Common Share certificates outstanding as of the Record
Date, by such Common Share certificate together with a copy of this Summary of Rights.
3. This First Amendment shall be effective as of the date hereof and, except as expressly set
forth herein, the Rights Agreement shall remain in full force and effect and be otherwise
unaffected hereby.
4. This First Amendment may be executed in any number of counterparts, each of which, when
executed, shall be deemed to be an original and all such counterparts shall together constitute one
and the same document.
3
IN WITNESS WHEREOF, the parties have executed this First Amendment as of the date first
written above.
|
|
|
|
|
|
QUESTCOR PHARMACEUTICALS, INC.
|
|
|
By: |
/s/
James L. Fares |
|
|
|
Name: |
James L. Fares |
|
|
|
Title: |
President and Chief Executive Officer |
|
|
|
|
|
|
|
|
COMPUTERSHARE TRUST COMPANY, INC.
|
|
|
By: |
/s/
Kellie Gwinn |
|
|
|
Name: |
Kellie Gwinn |
|
|
|
Title: |
Vice President |
|
|
|
By: |
/s/
John M. Wahl |
|
|
|
Name: |
John M. Wahl |
|
|
|
Title: |
Corporate Trust Officer |
|
|
4